Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion

BACKGROUND: The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral trop...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Bielack, S S, Cox, M C, Nathrath, M, Apel, K, Blattmann, C, Holl, T, Jenewein, R, Klenk, U, Klothaki, P, Müller-Abt, P, Ortega-Lawerenz, S, Reynolds, M, Scheer, M, Simon-Klingenstein, K, Stegmaier, S, Tupper, R, Vokuhl, C, von Kalle, T
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6859811/
https://ncbi.nlm.nih.gov/pubmed/31738425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz382
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki